<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_UI_Indonesia_Safety skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:UI Indonesia/Safety</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar-inner"><DIV class="container-fluid"><DIV class="navbar-header"><A class="navbar-brand" href="https://2018.igem.org/Team:UI_Indonesia">Home</A></DIV><DIV class="collapse navbar-collapse" id="myNavbar"><UL class="nav navbar-nav navbar-right"><LI class="dropdown navbar-project"><A href="https://2018.igem.org/Team:UI_Indonesia/Project">Project</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Project#">Overview</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Project#ourproject">Our Project</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Project#resultsanddiscuccions">Results and Discussions</A></LI></UL><LI class="navbar-parts"><A href="https://2018.igem.org/Team:UI_Indonesia/Parts">Parts</A></LI><LI class="navbar-safety current"><A href="https://2018.igem.org/Team:UI_Indonesia/Safety">Safety</A></LI><LI class="dropdown navbar-interlab"><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab">InterLab</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab#intro">Introduction</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab#materials">Materials and Equipment</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab#methods">Methods</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab#results">Results and Discussions</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/InterLab#conclusions">Conclusions</A></LI><LI class="navbar-model"><A href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</A></LI><LI class="dropdown navbar-humanpractice"><A href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Integrated Human Practice</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Public_Engagement">Education and Public Engagement</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices#catalogue">Human Practice Catalogue</A></LI><LI class="navbar-improve"><A href="https://2018.igem.org/Team:UI_Indonesia/Improve">Improve</A></LI><LI class="navbar-team"><A href="https://2018.igem.org/Team:UI_Indonesia/Team">Team</A></LI><LI class="navbar-collaborations"><A href="https://2018.igem.org/Team:UI_Indonesia/Collaborations">Collaborations</A></LI><LI class="dropdown navbar-attributions"><A href="https://2018.igem.org/Team:UI_Indonesia/Attributions">Attributions</A></LI><LI><A href="https://2018.igem.org/Team:UI_Indonesia/MedalCriteria">Medal Criteria</A></LI></DIV></DIV></DIV><DIV class="bgimg-1 w3-display-container w3-opacity-min" id="intro"><DIV class="w3-display-middle" style="white-space:nowrap;"><SPAN class="w3-center w3-padding-large w3-black w3-xlarge w3-wide w3-animate-opacity">SAFETY AND SECURITY ASPECTS</SPAN></DIV></DIV><DIV class="w3-content w3-container w3-padding-64"><H5>In accordance to the iGEM safety rules, our team used organism classified in the Risk Group 1, such as Escherichia coli K-12-strain derivates. To ensure the safety of ourselves and the project, our lab team worked in a BSL-1 (Biosafety Level 1) laboratory, certified internationally by WHO and CEN, in the Institute of Human Virology and Cancer Biology of the Faculty of Medicine, University of Indonesia. The safety criteria of this lab include risk assessment for each project, safety trainings, and standard operational procedures. Several lab administrative strategies are available such as medical surveillance and vaccination for those working with potentially infected human tissues, accident report, and safety drills.</H5><H5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in <A href="http://parts.igem.org/Part:BBa_K2607000" style="color:blue">http://parts.igem.org/Part:BBa_K2607000</A> Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.</H5><H6 align="center"><B>Figure 1</B>. One of our lab member (<I>Left</I>) interviews Mrs. Aroem (<I>Right</I>) for asking any advices and suggestions regarding teamâ€™s project and lab safety.</H6><H5>As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.</H5></DIV><FOOTER class="w3-center w3-green w3-padding-64 w3-opacity w3-hover-opacity-off"><DIV class="w3-xlarge w3-section">Team UI Indonesia igemui2018@gmail.com
  </DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></BODY></HTML>